Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Fa Yi Xue Za Zhi ; 32(1): 40-4, 2016 Feb.
Artigo em Zh | MEDLINE | ID: mdl-27295856

RESUMO

OBJECTIVE: To explore the correlation between the interleukin-17 (IL-17) level of peripheral blood and aggression of bipolar mania. METHODS: Thirty-six patients of bipolar mania were selected as experimental group by DSM-IV-TR and received treatment with quetiapine and lithium. Thirty-six healthy volunteers with similar age and gender were selected as control group. The level of IL-17 at baseline in each group and the level of IL-17 in the experimental group after treatment for 2, 4 and 8 weeks were detected by ELISA. RESULTS: The level of IL-17 in experimental group at baseline, after treatment for 2 and 4 weeks were all significantly higher than that in control group. After 8 weeks treatment, there was no significant difference between the two groups (P > 0.05). After 2, 4 and 8 weeks treatment, the total score and aggression score of Young Mania Rating Score (YMRS) were significantly lower than the baseline level (P < 0.05). In experimental group, the level of IL-17 was positively correlated with the two scores of YMRS at baseline (P < 0.05). CONCLUSION: Bipolar mania may be related to the up-regulation of IL-17. The level of IL-17 is related to the severity of manic symptoms at baseline, especially aggression symptom.


Assuntos
Agressão/efeitos dos fármacos , Antipsicóticos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Interleucina-17/sangue , Compostos de Lítio/uso terapêutico , Fumarato de Quetiapina/uso terapêutico , Biomarcadores/sangue , Transtorno Bipolar/sangue , Transtorno Bipolar/diagnóstico , Estudos de Casos e Controles , Manual Diagnóstico e Estatístico de Transtornos Mentais , Método Duplo-Cego , Humanos , Interleucina-17/metabolismo , Compostos de Lítio/efeitos adversos , Resultado do Tratamento
2.
Oncol Lett ; 19(3): 2097-2106, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32194707

RESUMO

The present study aimed to investigate the curative effect of high-dose methotrexate (HD-MTX) combined with teniposide (Vm26) vs. HD-MTX alone in the treatment of primary central nervous system lymphoma (PCNSL), in order to provide data for assisting decisions associated with clinical treatment. Data from 56 patients with PCNSL admitted in Shanghai Huashan Hospital (Shanghai, China) from January 2009 to December 2014 were included into the present study. Clinical data, curative effects and prognosis of patients in these two groups were retrospectively analyzed using SPSS 20 statistical software. In the HD-MTX+Vm26 group, 12 patients (42.85%) achieved complete remission (CR) and 10 patients (35.71%) achieved partial remission (PR), while in the HD-MTX group 7 patients (25%) achieved CR and 11 patients (39.29%) achieved PR (P=0.158). The median progression-free survival (PFS) time was 22 months in the HD-MTX+Vm26 group and 12 months in the HD-MTX group (P=0.019). The median overall survival time was 57 months in the HD-MTX+Vm26 group, and 28 months in the HD-MTX group (P=0.013). Compared with HD-MTX alone, the combined treatment of HD-MTX+Vm26 had an improved curative effect in the treatment of PCNSL, effectively controlled tumor progression in patients, prolonged survival time and improved prognosis. Age was an independent prognostic factor in patients with PCNSL. Patients with an age of ≤60 years exhibited longer PFS compared with patients with an age of >60 years.

3.
Chin Med J (Engl) ; 131(19): 2297-2301, 2018 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-30246715

RESUMO

BACKGROUND: Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component). So far, different effects on both BDNF and N400 were reported in relation to various antipsychotic treatments. However, few studies have been conducted on the mechanism of risperidone and paliperidone on BDNF and N400. This study aimed to compare the effects of risperidone and paliperidone on BDNF and the N400 component of the event-related brain potential in patients with first-episode schizophrenia. METHODS: Ninety-eight patients with first-episode schizophrenia were randomly divided into the risperidone and paliperidone groups and treated with risperidone and paliperidone, respectively, for 12 weeks. Serum BDNF level, the latency, and amplitude of the N400 event-related potential before and after the treatment and Positive and Negative Syndrome Scale (PANSS) scores were compared between the two groups. RESULTS: A total of 94 patients were included in the final analysis (47 patients in each group). After the treatment, the serum BDNF levels in both groups increased (all P < 0.01), while no significant difference in serum BDNF level was found between the groups before and after the treatment (all P > 0.05). After the treatment, N400 amplitudes were increased (from 4.73 ± 2.86 µv and 4.51 ± 4.63 µv to 5.35 ± 4.18 µv and 5.52 ± 3.08 µv, respectively) under congruent condition in both risperidone and paliperidone groups (all P < 0.01). Under incongruent conditions, the N400 latencies were shortened in the paliperidone group (from 424.13 ± 110.42 ms to 4.7.41 ± 154.59 ms, P < 0.05), and the N400 amplitudes were increased in the risperidone group (from 5.80 ± 3.50 µv to 7.17 ± 5.51 µv, P < 0.01). After treatment, the total PANSS score in both groups decreased significantly (all P < 0.01), but the difference between the groups was not significant (P > 0.05). A negative correlation between the reduction rate of the PANSS score and the increase in serum BDNF level after the treatment was found in the paliperidone group but not in the risperidone group. CONCLUSIONS: Both risperidone and paliperidone could increase the serum BDNF levels in patients with first-episode schizophrenia and improve their cognitive function (N400 latency and amplitude), but their antipsychotic mechanisms might differ.


Assuntos
Antipsicóticos/farmacologia , Fator Neurotrófico Derivado do Encéfalo/efeitos dos fármacos , Palmitato de Paliperidona/farmacologia , Risperidona/farmacologia , Esquizofrenia/tratamento farmacológico , China , Eletroencefalografia , Potenciais Evocados/efeitos dos fármacos , Feminino , Humanos , Masculino
4.
Chin Med J (Engl) ; 131(3): 301-306, 2018 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-29363645

RESUMO

BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) and event-related potentials (ERPs) are a noninvasive technique that widely used in neurophysiological field. Although rTMS has shown clinical utility for a number of neurological conditions, Recently,there was little understanding of the the efficacy of rTMS on Schizophrenia(SZ) and the change of ERP between before and after rTMS treatment. The objective of this study was to investigate the characteristics of N400, mismatch negativity (MMN), and P300 before and after treatment with rTMS in SZ. METHODS: One hundred and twenty-seven SZ patients hospitalized in Shanghai Mental Health Center from March 2015 to July 2017, divided into two groups (85 patients were recruited as rTMS group and 42 were recruited as sham rTMS [ShrTMS] group) and 76 normal controls (NCs) who were the staff and refresher staff in our hospital were recruited at the same time. A Chinese-made rTMS and a Runjie WJ-1 ERPs instrument were used in the present experiment. N400 was elicited by congruent and noncongruent Chinese idioms. After rTMS treatment, N400, P300, and MMN characteristics were compared with those before treatment and NC group. RESULTS: Compared with NC, the SZ patients exhibited delays in N400, P300, and MMN latency and decreased N400, P300, and MMN amplitudes in their frontal area (P < 0.05). After 25 rTMS treatments, N400 amplitudes in the frontal area (elicited by idioms with same phonic and different shape and meaning and with different phonic, shape, and meaning) were increased in the SZ patients (P < 0.05). However, there was no significant change in N400 before and after treatment with ShrTMS in SZ patients (P > 0.05). Amplitudes for MMN and target P300 also increased in SZ patients after rTMS treatment (P < 0.05). CONCLUSIONS: Based on our preliminary findings, we believe that the combined usage of N400, MMN, and P300 could be a valuable index and an electrophysiological reference in evaluating the effects of rTMS treatment in SZ patients.


Assuntos
Eletroencefalografia/métodos , Potenciais Evocados , Esquizofrenia/terapia , Estimulação Magnética Transcraniana/métodos , Adulto , Encéfalo/fisiopatologia , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição de Risco , Esquizofrenia/fisiopatologia , Resultado do Tratamento , Adulto Jovem
5.
Schizophr Res ; 65(1): 9-14, 2003 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-14623368

RESUMO

Several studies have suggested that the transcriptional activity of the DRD4 gene may exert an important role in susceptibility to schizophrenia. To address this issue, we studied the association of schizophrenia and polymorphisms including -616C>G, -603T>del, -602G>del, 600G>C, -521C>T, -376C>T and a 120 bp tandem duplication polymorphism (120 bp repeat) in 1.2 kb upstream from the initiation codon in the promoter region of the DRD4 gene with 210 schizophrenic cases and 206 healthy controls. The results showed a significant excess of allele L of the 120 bp repeat in the schizophrenic patients compared to the controls (X(2)=8.585, df=1, P=0.003, OR=1.546, 95% CI=1.154-2.070). No significant difference was detected in the frequencies of genotype and allele of six other polymorphisms between the two groups. However, haplotypic distribution of 120 bp repeat, -616C>G, -602G>del, -521C>T and -376C>T was significantly different between case and control groups (P=0.005). This might cause the alteration of the transcriptional regulation of the DRD4 gene, as the consensus sequences of binding sites for several known transcription factors are involved in this region.


Assuntos
Polimorfismo Genético/genética , Receptores de Dopamina D2/genética , Esquizofrenia/genética , Psicologia do Esquizofrênico , Adulto , China , Feminino , Frequência do Gene/genética , Predisposição Genética para Doença/genética , Genótipo , Haplótipos/genética , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas Pol1 do Complexo de Iniciação de Transcrição/genética , Regiões Promotoras Genéticas/genética , Receptores de Dopamina D4 , Esquizofrenia/diagnóstico , Sequências de Repetição em Tandem/genética , Transcrição Gênica/genética
6.
PLoS One ; 8(5): e63089, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23658801

RESUMO

BACKGROUND: Internet addiction disorder (IAD) is now recognized internationally and is known to be linked with academic and social impairment. To date, we know little about its associated main biological factors. This study aimed to collect a carefully defined group of adolescents with IAD and an age- and gender-matched typically developing comparison group. We hypothesized that the young people with IAD would have higher rates of self-reported anxiety and depressive symptoms, have altered levels of peripheral blood dopamine, norepinephrine and serotonin. In addition, we hypothesized the hours spent online are correlated with the severity of depression and anxiety among these young people with IAD. METHODOLOGY/PRINCIPAL FINDING: A cross-sectional study of 20 adolescents who met Beard's criteria for IAD and 15 typically developing adolescents (comparison group) was conducted. All the participants completed the Self Rating Depression Scale (SDS), Self Rating Anxiety Scale (SAS), and the Screen for Child Anxiety Related Emotional Disorders (SCARED). Peripheral blood dopamine, serotonin and norepinephrine were assayed. The mean level of norepinephrine was lower in the IAD group than that in the typically developing participants, while dopamine and serotonin levels did not differ. The SDS, SAS and SCARED symptom scores were increased in the adolescents with IAD. A logistic regression analysis revealed that a higher SAS score and lower level of norepinephrine independently predicted IAD group membership. There was no significant correlation between hours spent online and scores of SAS/SDS in IAD group. CONCLUSIONS/SIGNIFICANCE: Increased self-reported anxiety and lower peripheral blood norepinephrine are independently associated with IAD.


Assuntos
Ansiedade/sangue , Comportamento Aditivo/sangue , Depressão/sangue , Dopamina/sangue , Norepinefrina/sangue , Serotonina/sangue , Adolescente , Ansiedade/complicações , Ansiedade/fisiopatologia , Ansiedade/psicologia , Comportamento Aditivo/complicações , Comportamento Aditivo/fisiopatologia , Comportamento Aditivo/psicologia , Estudos de Casos e Controles , China , Estudos Transversais , Depressão/complicações , Depressão/fisiopatologia , Depressão/psicologia , Feminino , Humanos , Internet , Masculino , Projetos de Pesquisa , Índice de Gravidade de Doença , Adulto Jovem
7.
Chin Med J (Engl) ; 126(3): 482-7, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23422111

RESUMO

BACKGROUND: Clinical outcome in patients with primary central nervous lymphoma (PCNSL) is variable and poorly predictable. This study investigated the association of clinical features and immune markers with prognosis of patients with PCNSL. METHODS: One hundred and fifteen newly diagnosed PCNSL patients at the study institution were considered eligible for this study. Clinical characteristics and biochemical assay data were collected. Immunohistochemical staining of Cyclin D3, Cyclin E, Foxp1, and LMO2 were performed. All cases were followed-up regularly. RESULTS: The common sites of involvement were frontal lobe (54.8%) and thalamus (16.5%). Diffuse large B-cell lymphoma composed of 96.5% of the cases. The median overall survival was 22 (4 - 41) months, and the 5-year survival rate was 22.8%. Age > 65 years, serum globulin > 40 g/L, large size of tumor, lymphocyte count ≥ 1 × 10(9)/L, and expression of Cyclin D3 and Cyclin E were associated with poor prognosis of PCNSL. Expressions of Foxp1, LMO2, and CD44 were not related to the survival. Expression of Cyclin E, large tumor size, and high serum globulin were independent prognostic factors for PCNSL. CONCLUSIONS: PCNSL prognosis is relatively poor. Age, high tumor burden, higher lymphocyte count, expression of Cyclin D3, and Cyclin E are inferior prognostic factors for PCNSL.


Assuntos
Neoplasias do Sistema Nervoso Central/metabolismo , Neoplasias do Sistema Nervoso Central/patologia , Linfoma/metabolismo , Linfoma/patologia , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Adulto , Idoso , Ciclina D3/metabolismo , Ciclina E/metabolismo , Feminino , Fatores de Transcrição Forkhead/metabolismo , Humanos , Imuno-Histoquímica , Proteínas com Domínio LIM/metabolismo , Masculino , Pessoa de Meia-Idade , Prognóstico , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Repressoras/metabolismo , Estudos Retrospectivos , Adulto Jovem
8.
Inorg Chem ; 47(7): 2362-7, 2008 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-18318478

RESUMO

Innovative infrared nonlinear optical crystals CsGe(BrxCl(1-x))3 were synthesized. Their powder X-ray diffraction patterns indicated that they had rhombohedral structures with (R3m, No. 160) space group symmetry. Their structural distortion increased with x. The Kurtz powder techniques revealed that the nonlinear optical efficiency of CsGeBr3 is about 9.64 times larger than that of rhombohedral CsGeCl3 and 28.29 times larger than that of KH2PO4 (KDP); most importantly, CsGe(BrxCl(1-x))3 is phase-matchable. The transparent infrared spectrum of rhombohedral CsGe(BrxCl(1-x))3 was extended to over 30 mum and demonstrated its potential in the field of nonlinear optics and applicability in the infrared region.

9.
Pharmacogenet Genomics ; 18(6): 449-57, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18408624

RESUMO

BACKGROUND: Brain-derived neurotrophic factor (BDNF) belongs to a family of the neurotrophin, which plays important roles in the neurodevelopment of dopaminergic-related systems and interacts with meso-limbic dopaminergic systems involved in the therapeutic response to antipsychotics. Functional experiments have suggested that BDNF may be involved in the etiology of schizophrenia. METHODS AND RESULTS: In this study, we genotyped two important functional polymorphisms in the BDNF gene using a sample of Han Chinese patients consisting of 340 schizophrenic patients and 343 healthy controls. We found a statistical difference in the 232-bp allele distribution of the BDNF gene (GT)n dinucleotide repeat polymorphism between the schizophrenic patients and controls. In early onset patients, the 234-bp allele had a risk role. For the chlorpromazine-induced extrapyramidal syndrome, the 230-bp allele and the 234-bp allele acted in opposite directions, that is, patients with the 230-bp allele of the (GT)n polymorphism exhibited a lower degree of induced extrapyramidal syndrome. Haplotype-based analysis also revealed a very important risk haplotype (P=0.0000226546). CONCLUSION: These findings suggest that BDNF plays an important role in the susceptibility to schizophrenia and that the (GT)n repeat polymorphism of the BDNF gene may be an independent contributor to the chlorpromazine treatment-sensitive form of schizophrenia.


Assuntos
Antipsicóticos/efeitos adversos , Povo Asiático/genética , Doenças dos Gânglios da Base/induzido quimicamente , Doenças dos Gânglios da Base/genética , Fator Neurotrófico Derivado do Encéfalo/genética , Clorpromazina/efeitos adversos , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética , Adulto , Alelos , Sequência de Bases , Estudos de Casos e Controles , China , Primers do DNA/genética , Repetições de Dinucleotídeos , Feminino , Frequência do Gene , Predisposição Genética para Doença , Haplótipos , Humanos , Masculino , Pessoa de Meia-Idade , Farmacogenética , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA